Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Onchilles Pharma

​​Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway
From Onchilles Pharma
Via Business Wire
Onchilles Expands Leadership Team to Advance First-in-Class Pan-Cancer Therapeutics Targeting the ELANE Pathway into Clinical Trials
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Announces Presentation of Data for the NEU-002 Program at SITC 2024
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Announces Presentation of Preclinical Data for N17350 at AACR 2023
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of Cancer
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Appoints Christopher Twitty, Ph.D., Chief Scientific Officer
From Onchilles Pharma
Via Business Wire
Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway
From Onchilles Pharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.